


## AMENDMENTS TO THE CLAIMS

JC17 Rec'd PCT/PTO 20 SEP 2005

Please amend the claims as follows:

1. (Original) A compound of the Formula (I):



(I)


or a salt, solvate, or physiologically functional derivative thereof wherein:


A is aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -CN, halo, -COOH, -C(O)NR<sup>4</sup>R<sup>5</sup>, -NRR', -N(R')S(O)<sub>2</sub>R, -N(R')C(O)R, or -N(R')C(O)NR<sup>4</sup>R<sup>5</sup>;

R is -H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, or heteroaryl;

R' is -H or C<sub>1</sub>-C<sub>3</sub> alkyl;

D is selected from the group consisting of:





$R^2$  is  $-H$ , halo,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, aryl, heteroaryl,  $-S(O)_2NR^4R^5$ ,  $-COOH$ ,  $-C(O)OR^6$ ,  $-C(O)NR^4R^5$ ,  $NRR'$ ,  $-N(H)C(O)NRR'$ ,  $-N(H)C(O)R$ , or  $-N(H)S(O)_2R$ ;

$q$  is 1, 2, 3, or 4;

$R^3$  is  $-H$ ,  $C_1-C_3$  alkyl, aryl, aralkyl, or heteroaryl;

$R^4$  is  $-H$  or  $C_1-C_3$  alkyl;

$R^5$  is  $-H$  or  $C_1-C_3$  alkyl; or

$R^4$  and  $R^5$  together with the nitrogen to which they are attached form a heterocycl ring, said ring optionally containing 1 or 2 additional oxygen,  $S(O)_m$ , or nitrogen atoms; said nitrogen atoms being optionally substituted by a  $C_1-C_3$  alkyl group;

$m$  is 0, 1, or 2; and

$R^6$  is  $C_1-C_6$  alkyl.

2.(New) The compound of claim 1 wherein:

A is aryl optionally substituted with at least one  $R^1$  group, heteroaryl optionally substituted with at least one  $R^1$  group,  $C_1-C_6$  alkenyl,  $C_1-C_6$  alkynyl,  $-CN$ , halo,  $-COOH$ ,  $-C(O)NR^4R^5$ ,  $-NRR'$ ,  $-N(R')S(O)_2R$ ,  $-N(R')C(O)R$ , or  $-N(R')C(O)NR^4R^5$ ;


R is  $-H$ ,  $C_1-C_6$  alkyl, aryl, or heteroaryl;

$R'$  is  $-H$  or  $C_1-C_3$  alkyl;

$R^1$  is  $C_1-C_6$  alkyl, aryl,  $C_1-C_6$  alkoxy, aryloxy, halo,  $-COOH$ ,  $-CN$ ,  $-S(O)_2NR^4R^5$ ,  $-S(O)_2R$ ,  $-C(O)NR^4R^5$ ,  $-NRR'$ ,  $-N(H)C(O)NR^4R^5$ ,  $-O(CH_2)_nCOOH$ ,  $-(CH_2)_nCOOH$ ,  $-C(O)O(CH_2)_nR$ ,  $-(CH_2)_nN(H)C(O)OR$ , or  $-N(R')S(O)_2R$ ;

n is 1, 2, 3, or 4;

D is selected from the group consisting of:



$R^2$  is -H, halo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, heteroaryl,  $-S(O)_2NR^4R^5$ ,  $-COOH$ ,  $-C(O)OR^6$ , or  $-C(O)NR^4R^5$ ,  $NRR'$ ,  $-N(H)C(O)NRR'$ ,  $-N(H)C(O)R$ , or  $-N(H)S(O)_2R$ ;

q is 1, 2, 3, or 4;

$R^3$  is -H,  $C_1$ - $C_3$  alkyl, aryl, aralkyl, or heteroaryl;

$R^4$  is -H or  $C_1$ - $C_3$  alkyl;

$R^5$  is -H or  $C_1$ - $C_3$  alkyl; or

$R^4$  and  $R^5$  together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen,  $S(O)_m$ , or nitrogen atoms; said nitrogen atoms being optionally substituted by a  $C_1$ - $C_3$  alkyl group;

m is 0, 1, or 2; and

$R^6$  is  $C_1$ - $C_6$  alkyl.

3. (New) The compound of claim 1 wherein:


A is aryl optionally substituted with at least one  $R^1$  group or heteroaryl optionally substituted with at least one  $R^1$  group;

R is -H,  $C_1$ - $C_6$  alkyl, aryl, or heteroaryl;

$R'$  is -H or  $C_1$ - $C_3$  alkyl;

$R^1$  is  $C_1$ - $C_6$  alkyl, aryl,  $C_1$ - $C_6$  alkoxy, aryloxy, halo, -COOH, -CN,  $-S(O)_2NR^4R^5$ ,  $-S(O)_2R$ ,  $-C(O)NR^4R^5$ , -NRR', -N(H)C(O)NR<sup>4</sup>R<sup>5</sup>,  $-O(CH_2)_nCOOH$ ,  $-(CH_2)_nCOOH$ ,  $-C(O)O(CH_2)_nR$ ,  $-(CH_2)_nN(H)C(O)OR$ , or  $-N(R')S(O)_2R$ ;

D is selected from the group consisting of:



$R^2$  is -H, halo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, heteroaryl,  $-S(O)_2NR^4R^5$ , -COOH,  $-C(O)OR^6$ , or  $-C(O)NR^4R^5$ , NRR', -N(H)C(O)NRR', -N(H)C(O)R, or  $-N(H)S(O)_2R$ ;

q is 1, 2, 3, or 4;

R<sup>3</sup> is -H, C<sub>1</sub>-C<sub>3</sub> alkyl, aryl, aralkyl, or heteroaryl;

R<sup>4</sup> is -H or C<sub>1</sub>-C<sub>3</sub> alkyl;

R<sup>5</sup> is -H or C<sub>1</sub>-C<sub>3</sub> alkyl; or

R<sup>4</sup> and R<sup>5</sup> together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen, S(O)<sub>m</sub>, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C<sub>1</sub>-C<sub>3</sub> alkyl group;

m is 0, 1, or 2; and

R<sup>6</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl.


4. (New) The compound of claim 1 wherein:

A is C<sub>1</sub>-C<sub>6</sub> alkenyl or C<sub>1</sub>-C<sub>6</sub> alkynyl;

R is -H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, or heteroaryl;

R' is -H or C<sub>1</sub>-C<sub>3</sub> alkyl;

D is selected from the group consisting of:



$R^2$  is -H, halo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, heteroaryl,  $-S(O)_2NR^4R^5$ ,  $-COOH$ ,  $-C(O)OR^6$ , or  $-C(O)NR^4R^5$ ,  $NRR'$ ,  $-N(H)C(O)NRR'$ ,  $-N(H)C(O)R$ , or  $-N(H)S(O)_2R$ ;

q is 1, 2, 3, or 4;

$R^3$  is -H,  $C_1$ - $C_3$  alkyl, aryl, aralkyl, or heteroaryl;

$R^4$  is -H or  $C_1$ - $C_3$  alkyl;

$R^5$  is -H or  $C_1$ - $C_3$  alkyl; or

$R^4$  and  $R^5$  together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen,  $S(O)_m$ , or nitrogen atoms; said nitrogen atoms being optionally substituted by a  $C_1$ - $C_3$  alkyl group;

m is 0, 1, or 2; and

$R^6$  is  $C_1$ - $C_6$  alkyl.


5. (New) The compound of claim 1 wherein:


A is -CN,  $-COOH$ , or  $-C(O)NR^4R^5$ ;

R is -H,  $C_1$ - $C_6$  alkyl, aryl, or heteroaryl;

$R'$  is -H or  $C_1$ - $C_3$  alkyl;

D is selected from the group consisting of:





$R^2$  is  $-H$ , halo,  $C_1$ - $C_6$  alkyl,  $-COOH$ ,  $C_1$ - $C_6$  alkoxy, heteroaryl,  $-S(O)_2NR^4R^5$ ,  $-C(O)OR^6$ , or  $-C(O)NR^4R^5$ ,  $NRR'$ ,  $-N(H)C(O)NRR'$ ,  $-N(H)C(O)R$ , or  $-N(H)S(O)_2R$ ;

$q$  is 1, 2, 3, or 4;

$R^3$  is  $-H$ ,  $C_1$ - $C_3$  alkyl, aryl, aralkyl, or heteroaryl;

$R^4$  is  $-H$  or  $C_1$ - $C_3$  alkyl;

$R^5$  is  $-H$  or  $C_1$ - $C_3$  alkyl; or

$R^4$  and  $R^5$  together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen,  $S(O)_m$ , or nitrogen atoms; said nitrogen atoms being optionally substituted by a  $C_1$ - $C_3$  alkyl group;

$m$  is 0, 1, or 2; and

$R^6$  is  $C_1$ - $C_6$  alkyl.


6. (New) The compound of claim 1 wherein:

A is  $-NRR'$ ,  $-N(R')S(O)_2R$ ,  $-N(R')C(O)R$ , or  $-N(R')C(O)NR^4R^5$ ;

R is  $-H$ ,  $C_1$ - $C_6$  alkyl, aryl, or heteroaryl;

$R'$  is  $-H$  or  $C_1$ - $C_3$  alkyl;

D is selected from the group consisting of:



$R^2$  is  $-H$ , halo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, heteroaryl,  $-S(O)_2NR^4R^5$ ,  $-COOH$ ,  $-C(O)OR^6$ , or  $-C(O)NR^4R^5$ ,  $NRR'$ ,  $-N(H)C(O)NRR'$ ,  $-N(H)C(O)R$ , or  $-N(H)S(O)_2R$ ;

$q$  is 1, 2, 3, or 4;

$R^3$  is  $-H$ ,  $C_1$ - $C_3$  alkyl, aryl, aralkyl, or heteroaryl;

$R^4$  is  $-H$  or  $C_1$ - $C_3$  alkyl;

$R^5$  is  $-H$  or  $C_1$ - $C_3$  alkyl; or

$R^4$  and  $R^5$  together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen,  $S(O)_m$ , or nitrogen atoms; said nitrogen atoms being optionally substituted by a  $C_1$ - $C_3$  alkyl group;


$m$  is 0, 1, or 2; and

$R^6$  is  $C_1$ - $C_6$  alkyl.


7. (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and one or more of pharmaceutically acceptable carriers, diluents and excipients.




8. (New) The compound of claim 1, wherein D is selected from the group consisting of:




9. (New) The compound of claim 8, wherein D is:




10. (New) The compound of claim 8, wherein D is:




11. (New) The compound of claim 1, wherein D is selected from the group consisting of:



12. (New) The compound of claim 11, wherein D is:



13. (New) The compound of claim 11, wherein D is:



14. (New) The compound of claim 1, wherein said compound is selected from the group consisting of:

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

5-bromo-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-phenylpyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-thien-2-ylpyrazin-2-amine;

5-(4-aminophenyl)-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-pyridin-3-ylpyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-5-yl)pyrazin-2-amine;

3-[1-(2-methoxyethyl)-1H-benzimidazol-2-yl]-5-thien-2-ylpyrazin-2-amine;

3-(1H-benzimidazol-2-yl)-5-(3-fluorophenyl)pyrazin-2-amine;

3-(1H-benzimidazol-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;

4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]-N,N-dimethylbenzenesulfonamide;

3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)-5-[3-(methylsulfonyl)phenyl]pyrazin-2-amine;

3-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}propanoic acid;

{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

{3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

N-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}methanesulfonamide;

benzyl 4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoate;

5-[4-(benzyloxy)phenyl]-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

5-[1,1'-biphenyl-3-yl]-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoic acid;

tert-butyl 3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzylcabamate;

3 (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrrol-2-yl)pyrazin-2-amine;

3 (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-2-yl)pyrazin-2-amine; and

5-[(4-aminophenyl)ethynyl]-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

or a salt, solvate, or physiologically functional derivative thereof.

15. (New) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate ROCK-1 activity, comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.